Clearmind Medicine wins Yale IRB clearance to recruit patients for CMND-100 trial parts B and C

• Clearmind Medicine won Yale University IRB clearance to start recruiting patients for Parts B and C of its CMND-100 Phase I/II trial.
• The green light expands enrollment at Yale alongside existing recruiting sites, supporting development of the non-hallucinogenic AUD candidate.
• Part A safety readout met the primary endpoint in 24 participants, with no serious adverse events reported.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clearmind Medicine Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609080742PRIMZONEFULLFEED9822751) on September 08, 2026, and is solely responsible for the information contained therein.